Effects of cyclophosphamide on rat placental development

Area of Science:

• Toxicology
• Developmental Biology
• Reproductive Science

Background:

• Cyclophosphamide (CPA) is a widely used chemotherapeutic agent with known teratogenic potential.
• Understanding CPA's specific effects on placental morphology is crucial for assessing developmental risks.

Purpose of the Study:

• To investigate the morphological and histopathological effects of cyclophosphamide (CPA) exposure on rat placental development.
• To compare the impact of CPA administration at different gestational days (GD 12 vs. GD 14).

Main Methods:

• Pregnant rats received a single intraperitoneal dose of CPA (25 mg/kg) on GD 12 or GD 14.
• Control groups received 0 mg/kg CPA.
• Fetal and placental weights were measured, and external malformations were assessed.
• Histopathological examination of placental tissues, including labyrinth and basal zones, was performed.

Main Results:

• CPA treatment led to decreased fetal and placental weights in both treated groups.
• Complete fetal resorption occurred from GD 17 in the GD 12-treated group.
• External malformations were observed in the GD 14-treated group.
• Histopathology revealed CPA-induced apoptosis and proliferation inhibition in placental tissues.
• Specific reductions in syncytiotrophoblasts (labyrinth zone) and spongiotrophoblasts (basal zone) were noted.
• The severity of placental lesions was greater in the GD 12-treated group compared to the GD 14-treated group.

Conclusions:

• Cyclophosphamide exposure during critical periods of rat placental development causes significant morphological alterations.
• The timing of CPA exposure influences the severity and type of developmental toxicity observed.
• CPA disrupts placental cell populations, leading to reduced placental size and impaired fetal development, including resorption and malformations.